Long-term safety study of lerodalcibep in children with high cholesterol
Treatments studied
This study is a long-term follow-up for children and teens with familial hypercholesterolemia (a genetic condition causing very high cholesterol) who have already completed a previous study. It tests the safety and effectiveness of an investigational drug called lerodalcibep over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the earlier study (LIB003-008) and received the last dose at week 20, plus the week 24 visit.
- You must be between 6 and 17 years old.
- Your weight must be more than 40 pounds (18 kg) and your BMI must be between 17 and 42.
- You must be on a stable diet and taking your cholesterol-lowering medication consistently.
- You must not have any medical condition that could make participation unsafe, and if you are a female who can become pregnant, you must not be pregnant or breastfeeding and must agree to use effective contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication called QLC7401 for people with a genetic condition that causes very high cholesterol. It aims to lower cholesterol levels safely and may be an option for those who need better control.
This study tests an experimental daily pill (enlicitide decanoate) that lowers LDL ('bad') cholesterol in children and teens with a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to see if this medicine can safely help reduce their high cholesterol levels.
This trial tests if a new medicine, lerodalcibep, can safely lower cholesterol in children ages 6 to 17 who have a genetic condition called heterozygous familial hypercholesterolemia (HeFH). It aims to help children whose cholesterol stays high despite taking standard cholesterol-lowering drugs.
This Phase 3 study looks at the long-term safety and benefit of OLE LIB003 for people with very high cholesterol or heart disease risk who still need lower LDL (“bad cholesterol”). It’s likely a continuation study for participants who already did earlier LIB003 Phase 3 trials.
This trial tests a new injection called ART002g1 for people with a genetic condition that causes very high cholesterol. It aims to see if the drug is safe and can help lower cholesterol levels.
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
Hear when a new Heterozygous Familial Hypercholesterolemia (HeFH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.